# Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT02420860** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 113 (actual)

## Conditions studied

- Hematopoietic Cell Transplantation Recipient
- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Elotuzumab
- **DRUG:** Lenalidomide
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02420860
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-04-14
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420860, "Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02420860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*